摘要
目的:评价吡格列酮联用二甲双胍治疗2型糖尿病的临床疗效及安全性。方法:将102例2型糖尿病患者随机分为2组,治疗组采用吡格列酮联用二甲双胍治疗,对照组单用二甲双胍治疗,比较2组血糖和胰岛素指标的变化。结果:连用6个月后2组空腹血糖(FPG)、餐后2h血糖(P2hBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后2h胰岛素(P2hINS)、稳态胰岛素评价指数(HOMA-IR)水平均明显降低,与治疗前比较差异均有统计学意义(P<0.05);但治疗组治疗后FPG、P2hBG、HbA1c、FINS、P2hINS、HOMA-IR水平明显低于同期对照组水平,2组比较差异有统计学意义(P<0.05);2组不良反应少,均未见严重不良反应。结论:吡格列酮联用二甲双胍治疗2型糖尿病,能够明显降低血糖水平,改善胰岛素状态,且不良反应少。
OBJECTIVE:To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS:102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS:After 6 months of treatment,fasting plasma glucose(FPG),postprandial 2 h blood glucose(P2hBG),glycosylated hemoglobin(HbA1c),fasting insulin(FINS),postprandial 2 h insulin(P2hINS),steady-state assessment index of insulin(HOMA-IR) in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment(P0.05).After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance(P0.05);There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION:Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第24期2258-2259,共2页
China Pharmacy